Stéphanie Poulain
YOU?
Author Swipe
View article: Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study Open
View article: Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia Open
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial demonstrated interesting efficacy in a high-ris…
View article: Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia Open
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial showed interesting efficacy in a high-risk geno…
View article: Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression Open
Mycosis fungoides (MF) is the most prevalent primary cutaneous T-cell lymphoma, with an indolent or aggressive course and poor survival. The pathogenesis of MF remains unclear, and prognostic factors in the early stages are not well establ…
View article: New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia Open
Demonstration of LPL with a bone marrow biopsy is essential to reach a definitive diagnosis of WM. However, MYD88L265P and a typical WM immunophenotypic profile are valuable for the differential diagnosis of WM and relate…
View article: The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots
The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots Open
TP53 aberrations are a major predictive factor of resistance to chemoimmunotherapy in chronic lymphocytic leukemia (CLL), and an assessment of them before each line of treatment is required for theranostic stratification. Acquisition of su…
View article: Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Characteristics of patients with WM
View article: Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is k…
View article: Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Characteristics of patients with WM
View article: Data from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Data from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Purpose: Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4mut) as the most prevalent somatic mutations in Waldenström macroglobulinemia. CXCR4 mutation has proved to b…
View article: Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Table S1. Genomic characteristics of WM with TP53 aberration; Figure S1: Delineation of 17p minimal deleted region detected by SNP array in Waldenstrom's macroglobulinemia; Figure S2. (1) Nutlin-3a effects on WM cells. Impact of nutlin-3a …
View article: Data from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Data from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Purpose: Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4mut) as the most prevalent somatic mutations in Waldenström macroglobulinemia. CXCR4 mutation has proved to b…
View article: Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Table S1. Genomic characteristics of WM with TP53 aberration; Figure S1: Delineation of 17p minimal deleted region detected by SNP array in Waldenstrom's macroglobulinemia; Figure S2. (1) Nutlin-3a effects on WM cells. Impact of nutlin-3a …
View article: Supplemental Table 1 Gene expression profilling from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Supplemental Table 1 Gene expression profilling from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Gene expression profilling : List of deregulated gene identified by gene expression profilling using U133 Plus 2.0 arrays (Affymetrix, USA)
View article: List of pathways analyzed for GSEA from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
List of pathways analyzed for GSEA from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
List of pathways analyzed for GSEA
View article: Supplemental Table 1 Gene expression profilling from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
Supplemental Table 1 Gene expression profilling from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
Gene expression profilling : List of deregulated gene identified by gene expression profilling using U133 Plus 2.0 arrays (Affymetrix, USA)
View article: List of pathways analyzed for GSEA from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia
List of pathways analyzed for GSEA from Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia Open
List of pathways analyzed for GSEA
View article: Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is k…
View article: Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia Open
View article: Diagnostics in Waldenström’s Macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Diagnostics in Waldenström’s Macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia Open
The diagnosis of Waldenström’s macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress …
View article: Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider
Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider Open
Ibrutinib, a first-class Bruton tyrosine kinase inhibitor, is known to be associated with adverse bleeding events and has been recently approved for the treatment of relapse Waldenström macroglobulinemia (WM). Here, we report the exhaustiv…
View article: P1257: MOLECULAR CHARACTERIZATION AND CLONAL EVOLUTION OF MYCOSIS FUNGOIDES
P1257: MOLECULAR CHARACTERIZATION AND CLONAL EVOLUTION OF MYCOSIS FUNGOIDES Open
Background: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma with a frequency of over 50% of all cases. MF has an indolent progression over several years through different stages. Symptoms evolve from a non-aggre…
View article: Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic‐Tγδ‐cell lymphoma
Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic‐Tγδ‐cell lymphoma Open
Here we present the case of an hepato‐splenic‐Tγδ‐cell lymphoma interestingly occurring in a non‐immunocompromised patient, with profuse telangiectasias giving originally misleading orientation towards the diagnosis of B angiotropic lympho…
View article: Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
Mast cell density and its clinical relevance in Waldenström's macroglobulinemia Open
The presence of numerous mast cells (MCs) mixed with tumor cells in the bone marrow (BM) is a hallmark of the diagnosis of Waldenström's macroglobulinemia (WM). MCs have been shown to support lymphoplasmacytic cell growth, but there is thu…
View article: <scp>TP53</scp> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
<span>TP53</span> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia Open
International audience
View article: Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepato-splenic-Tγδ-cell lymphoma
Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepato-splenic-Tγδ-cell lymphoma Open
Here we present the case of an hepato-splenic-Tγδ-cell lymphoma interestingly occurring in a non-immunocompromised patient, with profuse telangiectasias giving originally misleading orientation towards the diagnosis of B angiotropic lympho…
View article: Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (<scp>FILO</scp>)
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (<span>FILO</span>) Open
TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary …
View article: Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia Open
We present the results of a phase 2 study evaluating the combination of obinutuzumab + idelalisib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). The goal was to determine the safety and efficacy of a fixed-duration chemot…
View article: Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells
Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells Open
Activating mutations of MYD88 ( MYD88 L265P being the far most frequent) are found in most cases of Waldenström macroglobulinemia (WM) as well as in various aggressive B-cell lymphoma entities with features of plasma cell (PC) differentiat…
View article: Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia Open
Not available.